GYRE (Gyre Therapeutics, Inc. Common Stock) Stock Analysis - Community

Gyre Therapeutics, Inc. Common Stock (GYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, GYRE trades at $6.04 with a market cap of $624.86M and a P/E ratio of 100.58. GYRE moved -3.35% today. Year to date, GYRE is -23.74%; over the trailing twelve months it is -47.02%. Its 52-week range spans $6.01 to $19.00. Analyst consensus is buy with an average price target of $19.00. Rallies surfaces GYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

How does the Rallies community trade GYRE?

Rallies community data for GYRE shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.

GYRE Key Metrics

Key financial metrics for GYRE
MetricValue
Price$6.04
Market Cap$624.86M
P/E Ratio100.58
EPS$0.06
Dividend Yield0.24%
52-Week High$19.00
52-Week Low$6.01
Volume0
Avg Volume0
Revenue (TTM)$116.59M
Net Income$9.88M
Gross Margin95.36%

Latest GYRE News

Recent GYRE Insider Trades

  • Luo Ying sold 10.14K (~$81.49K) on May 6, 2026.
  • Luo Ying sold 179 (~$1.43K) on May 5, 2026.
  • Ma Songjiang sold 558 (~$5.62K) on May 28, 2025.

GYRE Analyst Consensus

2 analysts cover GYRE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.00.

Common questions about GYRE

How does the Rallies community trade GYRE?
Rallies community data for GYRE shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
Does Rallies show retail investor data for GYRE?
Rallies shows anonymized community ownership, retail positioning, sentiment, and portfolio context for GYRE when enough community data is available.
Is GYRE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for GYRE. It does not provide personalized investment advice.
GYRE

GYRE